News und Analysen
One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
The Hidden Gem in Novavax's Pipeline You'll Want to Watch
If you've looked into Novavax (NASDAQ: NVAX), you know the clinical-stage biotech's primary focus is on its experimental RSV F vaccine. Novavax has had its fair share of ups and downs with that
Why I Love Celgene Corporation
Stocks aren't like children. It's not a problem at all if you don't love each stock in your investment portfolio equally. You can have favorites without even the smallest amount of guilt.In my case
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made
3 Stocks to Buy With Dividends Yielding More Than 3%
Dividend stocks offer both income and long-term growth prospects. Smart dividend investors focus on the stocks that have the best chances of giving them both, maximizing their returns. Among
Novo Nordisk A/S Continues Its Comeback
Novo Nordisk (NYSE: NVO) released earnings for the first half of 2017, and while revenue growth wasn't spectacular, considering how last year went for the diabetes specialist, investors will take it.M
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
The Best Marijuana and Precision Medicine Stocks to Buy Might Not Be the Companies You Think
The marijuana market may be on its way to being worth $25 billion in 2021, and advances in DNA research could lead to next-generation precision medicine worth billions of dollars in annual sales. Yet
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
How Intuitive Surgical, Inc. Makes Most of Its Money
Robots aren't as common in hospitals as waiting rooms are, but there are certainly a lot of robots out there now. You can thank Intuitive Surgical (NASDAQ: ISRG) in large part. Over 4,100 of the
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs
Here's Why Synergy Pharmaceuticals Inc. Is Falling Today
After posting a much higher loss than Wall Street expected, shares of Synergy Pharmaceuticals (NASDAQ: SGYP), a commercial-stage biopharma focused on diseases of the gastrointestinal system, fell as
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
Why Red Robin Gourmet Burgers, Hertz Global Holdings, and Novo Nordisk Jumped Today
The stock market fell again on Wednesday, posting what has become an increasingly rare two-day losing streak. Major benchmarks gave up modest amounts of ground in the wake of some disappointing
Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
Despite upbeat recent developments, shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) fell 15.3% during Wednesday's session. The biotech reported solid progress with clinical-stage candidates
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts
Shares of Exelixis (NASDAQ: EXEL), a biotechnology company focused on the development of drugs to treat various types of cancer, moved steadily higher by a cool 10% in July, according to data from S&P
Becton Dickinson and Co Faces a Rough Comparator
Becton, Dickinson (NYSE: BDX) reported a small drop in revenue and a substantial loss in its third fiscal quarter, but both issues are easily explainable as long as you don't mind ignoring GAAP, which
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
Is This Why bluebird bio Dipped 10.5% in July?
bluebird bio (NASDAQ: BLUE), a clinical-stage biotech focused on gene therapy, fell more than 10% in July, according to S&P Global Market Intelligence. However, there wasn't any news released during
Illumina Introduces a New Genomic Era
Illumina's (NASDAQ: ILMN) second-quarter earnings crushed expectations last week. Investors cheered the company's raised guidance, and the stock is up more than 15% since the report.Illumina's genomic
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market